bendamustine hydrochloride has been researched along with Granuloma, Hodgkin in 57 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.75) | 18.7374 |
| 1990's | 1 (1.75) | 18.2507 |
| 2000's | 2 (3.51) | 29.6817 |
| 2010's | 32 (56.14) | 24.3611 |
| 2020's | 21 (36.84) | 2.80 |
| Authors | Studies |
|---|---|
| Akay, OM; Altuntaş, F; Başcı, S; Büyükkurt, N; Dal, MS; Ferhanoğlu, B; Güneş, AK; Hindilerden, F; Kızıl Çakar, M; Korkmaz, S; Mehtap, Ö; Nalçacı, M; Özet, G; Ulaş, T; Uncu Ulu, B; Yanardağ Açık, D; Yiğenoğlu, TN; Yönal Hindilerden, İ | 1 |
| Absalon, MJ; Castellino, SM; Forlenza, CJ; Franklin, A; Gulati, N; Keller, FG; Mauguen, A; Shukla, N | 1 |
| Bolis, S; Botto, B; Cantonetti, M; Fabbri, A; Falchi, L; Galieni, P; Gini, G; Liberati, AM; Moretti, M; Pavone, V; Puccini, B; Pulsoni, A; Renzi, D; Rigacci, L | 1 |
| Buffardi, S; De Vito, R; Del Bufalo, F; Di Matteo, A; Di Ruscio, V; Locatelli, F; Mariggiò, E; Paganelli, V; Pagliara, D; Parasole, R; Petruzziello, F; Stocchi, F; Strocchio, L; Vinti, L | 1 |
| Afanasyev, B; Beynarovich, A; Borzenkova, E; Kondakova, E; Kozlov, A; Kulagin, A; Lepik, K; Mikhailova, N; Moiseev, I; Pirogova, O; Stelmakh, L; Volkov, N; Zalyalov, Y; Zubarovskaya, L | 1 |
| Agbetiafa, K; Amorim, S; Aubrais, R; Banos, A; Bellal, M; Besson, C; Bijou, F; Bonnet, C; Bouabdallah, K; Brice, P; Chartier, L; Chauchet, A; Cluzeau, T; Daguindau, N; Damaj, G; Delapierre, B; Durot, E; Fouillet, L; Gaulard, P; Herbaux, C; Laribi, K; Le Calloch, R; Parrens, MC; Schiano, JM; Sibon, D; Tournilhac, O | 1 |
| Amoroso, L; Beishuizen, A; Buffardi, S; Cole, PD; Cooper, S; Daw, S; Drachtman, RA; Francis, S; Harker-Murray, P; Hoppe, BS; Kelly, KM; Leblanc, T; Leger, KJ; Lisano, J; Mascarin, M; Mauz-Körholz, C; Michel, G; Rigaud, C; Sacchi, M | 1 |
| Al Batran, M; Al Darweesh, M; Al Garni, A; Al Hashmi, H; Al Naim, A; Al Zayer, M; Kaloyannidis, P; Kanfar, S | 1 |
| Amengual, JE; Tolu, SS | 1 |
| Amin, NH; El-Saadi, MT; Mohamed, NR; Sharkawi, MMZ | 1 |
| Crews, KR; Flerlage, JE; Niloy, KK; Panetta, JC; Purvis, KN; Swanson, HD; Zhou, Y | 1 |
| Kuittinen, O; Kuitunen, H; Kuusisto, MEL; Paloneva, T; Prusila, REI; Rämet, M; Teppo, HR; Väyrynen, JP; Vuolio, T | 1 |
| Beishuizen, A; Boes, M; Diez, C; Greve, P; Hagleitner, M; Loeffen, J; Meyer-Wentrup, F; Peperzak, V; Veening, M | 1 |
| Argnani, L; Botto, B; Broccoli, A; Corradini, P; Fanti, S; Pinto, A; Re, A; Stefoni, V; Vitolo, U; Zinzani, PL | 1 |
| Egle, A; Greil, R; Jäger, U; Keil, F; Lehner, B; Magnes, T; Melchardt, T; Panny, M; Sillaber, C; Simonitsch-Klupp, I; Skrabs, C; Staber, P; Wagner, SM | 1 |
| Anastasia, A; Annechini, G; Bonfichi, M; Carlo-Stella, C; Castagna, L; Di Renzo, N; Giordano, L; Gotti, M; Liberati, AM; Luminari, S; Mazza, R; Merli, F; Peli, A; Pulsoni, A; Re, A; Ricci, F; Santoro, A; Zanni, M; Zilioli, VR | 1 |
| Advani, R; Agura, E; Ansell, SM; Behler, C; Bociek, RG; Caimi, P; Cheung, E; Crosswell, HE; Forero-Torres, A; Islas-Ohlmayer, M; Josephson, N; LaCasce, AS; Matous, J; O'Connor, OA; Sawas, A; Vose, J; Wang, Y | 2 |
| Bonanno, V; Caruso, AL; Cascavilla, N; Chiarenza, A; Consoli, U; Crescimanno, A; De Santis, G; Di Raimondo, F; Greco, A; Guarini, A; Iannitto, E; Li Gioi, F; Mannina, D; Mantuano, S; Minoia, C; Musso, M; Pavone, E; Pirosa, MC; Porretto, F; Ricciuti, G; Romano, A; Salerno, M; Scalone, R; Scalzulli, PR; Tarantini, G | 1 |
| Beaven, AW; Brenner, MK; Buchanan, FB; Cheng, CJ; Dittus, C; Dotti, G; Eldridge, PW; Gee, AP; Grilley, BJ; Grover, NS; Heslop, HE; Ivanova, A; Lulla, PD; McKay, KL; Mehta, B; Morrison, K; Park, SI; Ramos, CA; Rooney, CM; Savoldo, B; Serody, JS; Shea, TC; Wang, T; Wu, MF | 1 |
| Cheng, B; Connors, JM; Crump, M; Deng, C; Kuruvilla, J; Lue, JK; Ma, H; Marchi, E; Montanari, F; O'Connor, OA; Savage, KJ; Sawas, A; Villa, D | 1 |
| Földeák, D; Gopcsa, L; Illés, Á; Miltényi, Z; Pinczés, LI; Piukovics, K; Szabó, R; Szomor, Á | 1 |
| Ardeshna, KM; Carpenter, B; Daw, S; Grandage, V; Hough, R; Humphries, P; Lambert, J; McMillan, A; Menezes, L; O'Neill, AT; Shah, R; Townsend, W; Virchis, A; Von Both, K | 1 |
| Bazarbachi, A; El Cheikh, J; Fares, E; Haffar, B; Ibrahim, A; Jisr, T; Kharfan-Dabaja, MA; Mahfouz, R; Massoud, R; Mougharbel, A; Youssef, A | 1 |
| Alenxandrova, K; Arfi-Rouche, J; Bourhis, JH; Castilla-Llorente, C; Danu, A; Ghez, D; Khalife-Saleh, N; Koscielny, S; Lapierre, V; Lazarovici, J; Legoupil, C; Michot, JM; Pilorge, S; Ribrag, V; Saleh, K | 1 |
| Chiappella, A; Vitolo, U | 1 |
| Haapasaari, KM; Karjalainen-Lindsberg, ML; Kuittinen, O; Marin, K; Pollari, M; Prusila, REI; Soini, Y; Turpeenniemi-Hujanen, T; Vornanen, M | 1 |
| Gordon, LI | 1 |
| Brice, P; Casasnovas, O; Clément, L; Ferlay, C; Gabarre, J; Ghesquières, H; Gyan, E; Malphettes, M; Morschhauser, F; Stamatoullas, A | 1 |
| Argnani, L; Broccoli, A; Celli, M; Derenzini, E; Pellegrini, C; Zinzani, PL | 1 |
| Moskowitz, A | 1 |
| Anastasia, A; Brusamolino, E; Carlo-Stella, C; Corradini, P; Giordano, L; Hohaus, S; Luminari, S; Pregno, P; Pulsoni, A; Rusconi, C; Salvi, F; Santoro, A; Viviani, S | 1 |
| Elsoueidi, R; Mourad, H; Mulat, A | 1 |
| Bramanti, S; Bruno-Ventre, M; Castagna, L; Ciceri, F; Corti, C; Crocchiolo, R; Gandolfi, S; Marktel, S; Peccatori, J; Sala, E; Santoro, A; Sarina, B | 1 |
| Argnani, L; Maglie, R; Pellegrini, C; Pileri, S; Zinzani, PL | 1 |
| Argnani, L; Broccoli, A; Cascavilla, N; Corradini, P; Hohaus, S; Merli, F; Motta, G; Tani, M; Vitolo, U; Viviani, S; Zinzani, PL | 1 |
| Illés, Á; Jóna, Á; Miltényi, Z; Simon, Z; Udvardy, M | 1 |
| Anderlini, P; Cheah, CY; Chihara, D; Fanale, MA; Fayad, LE; Fowler, NH; Hagemeister, FB; Horowitz, S; Nastoupil, LJ; Neelapu, SS; Nieto, Y; Oki, Y; Rodriguez, MA; Romaguera, JE; Samaniego, F; Sevin, A; Turturro, F; Wang, M; Westin, JR; Zhou, S | 1 |
| Zahid, MF | 1 |
| Anastasia, A; Annechini, G; Bonfichi, M; Carlo-Stella, C; Castagna, L; Di Renzo, N; Giordano, L; Gotti, M; Liberati, AM; Luminari, S; Mazza, R; Merli, F; Peli, A; Pulsoni, A; Re, A; Salvi, F; Santoro, A; Zilioli, VR | 1 |
| Venkatesan, P | 1 |
| Gibb, A; Howell, M; Linton, K; Radford, J | 1 |
| Amengual, JE; Connors, JM; Deng, C; Kalac, M; Kuruvilla, J; Lichtenstein, E; Lue, JK; Mapara, MY; O'Connor, OA; Rojas, C; Sawas, A; Turenne, I | 1 |
| Dougherty, DW; Friedberg, JW | 1 |
| Bauer, K; Brillant, C; Engert, A; Herbst, C; Kluge, S; Monsef, I; Skoetz, N | 1 |
| Annechini, G; Breccia, M; Cavalieri, E; D'Elia, GM; Danieli, R; De Angelis, F; Panfilio, S; Pulsoni, A | 1 |
| Caballero, MD; Capria, S; Cuberli, F; Falcioni, S; Ferrara, F; Galieni, P; Gaudio, F; Gherlinzoni, F; Giardini, C; Gobbi, M; Isidori, A; Malerba, L; Meloni, G; Ocio, EM; Rocchi, M; Santoro, A; Sarina, B; Specchia, G; Stefani, PM; Visani, G | 1 |
| Barna, S; Illés, Á; Magyari, F; Simon, Z; Udvardy, M; Váróczy, L | 1 |
| Moskowitz, AJ | 1 |
| Casini, M; Cavattoni, IM; Cortelazzo, S; Deola, S; Farsad, M; Mian, M; Pescosta, N | 1 |
| Amore, A; Angrilli, F; Arcamone, M; Califano, C; Corazzelli, G; Cox, MC; D'Arco, A; De Filippi, R; Falorio, S; Ferrara, F; Guarini, A; Iannitto, E; Musto, P; Pinto, A; Stelitano, C; Storti, S | 1 |
| Gerecitano, J; Graustein, T; Hamlin, PA; Horwitz, SM; Matasar, MJ; Moskowitz, AJ; Moskowitz, CH; Noy, A; Palomba, ML; Perales, MA; Portlock, CS; Straus, DJ; Zelenetz, AD | 1 |
| Cheson, BD; Diehl, V | 1 |
| Borchmann, P; Diehl, V; Engert, A; Schnell, R | 1 |
| Balfour, JA; Goa, KL | 1 |
| Anger, G; Herold, M; Höche, D; Kästner, R | 1 |
4 review(s) available for bendamustine hydrochloride and Granuloma, Hodgkin
| Article | Year |
|---|---|
Gemcitabine and other new cytotoxic drugs: will any find their way into primary therapy?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bendamustine Hydrochloride; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Histone Deacetylase Inhibitors; Hodgkin Disease; Humans; Lenalidomide; Nitrogen Mustard Compounds; Rituximab; Thalidomide; Vinblastine; Vinorelbine | 2010 |
Novel agents in Hodgkin lymphoma.
Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Brentuximab Vedotin; Everolimus; Histone Deacetylase Inhibitors; Hodgkin Disease; Humans; Immunoconjugates; Lenalidomide; Nitrogen Mustard Compounds; Protein Kinase Inhibitors; Sirolimus; Thalidomide | 2012 |
New drugs in the treatment of Hodgkin's disease.
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bendamustine Hydrochloride; Deoxycytidine; Drug Therapy; Gemcitabine; Hodgkin Disease; Humans; Idarubicin; Immunotoxins; Nitrogen Mustard Compounds; Vinblastine; Vinorelbine | 1998 |
Bendamustine.
Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Breast Neoplasms; Female; Half-Life; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Metabolic Clearance Rate; Nitrogen Mustard Compounds | 2001 |
11 trial(s) available for bendamustine hydrochloride and Granuloma, Hodgkin
| Article | Year |
|---|---|
Nivolumab and brentuximab vedotin with or without bendamustine for R/R Hodgkin lymphoma in children, adolescents, and young adults.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Brentuximab Vedotin; Child; Hodgkin Disease; Humans; Immunoconjugates; Neoplasm Recurrence, Local; Nivolumab; Treatment Outcome; Young Adult | 2023 |
First salvage treatment with bendamustine and brentuximab vedotin in Hodgkin lymphoma: a phase 2 study of the Fondazione Italiana Linfomi.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Brentuximab Vedotin; Combined Modality Therapy; Female; Hodgkin Disease; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Grading; Salvage Therapy; Tomography, X-Ray Computed; Treatment Outcome; Young Adult | 2019 |
Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Deoxycytidine; Disease-Free Survival; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Recurrence; Transplantation, Autologous | 2020 |
Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Combined Modality Therapy; Cyclophosphamide; Epitopes; Female; Hodgkin Disease; Humans; Immunotherapy, Adoptive; Ki-1 Antigen; Lymphocyte Depletion; Male; Middle Aged; Stem Cell Transplantation; Vidarabine; Young Adult | 2020 |
Prolonged progression free survival in a subset of responders to the combination of brentuximab vedotin and bendamustine in heavily treated patients with relapsed or refractory Hodgkin lymphoma: updated results from an international multi-center phase I/I
Topics: Bendamustine Hydrochloride; Brentuximab Vedotin; Hodgkin Disease; Humans; Immunoconjugates; Neoplasm Recurrence, Local; Progression-Free Survival | 2020 |
Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Brentuximab Vedotin; Disease-Free Survival; Female; Hodgkin Disease; Humans; Immunoconjugates; Male; Middle Aged; Recurrence; Salvage Therapy; Survival Rate; Time Factors | 2018 |
Brentuximab Vedotin in Combination With Dacarbazine or Bendamustine for Frontline Treatment of Hodgkin Lymphoma in Patients Aged 60 Years and Above: Interim Results of a Multi-Cohort Phase 2 Study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Brentuximab Vedotin; Cohort Studies; Dacarbazine; Female; Hodgkin Disease; Humans; Immunoconjugates; Male; Middle Aged; Neoplasm Recurrence, Local | 2016 |
Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study.
Topics: Adolescent; Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prospective Studies; Transplantation, Autologous; Vinblastine; Vinorelbine; Young Adult | 2016 |
BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Follow-Up Studies; Graft Survival; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Nitrogen Mustard Compounds; Recurrence; Remission Induction; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous | 2011 |
Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Hodgkin Disease; Humans; Male; Middle Aged; Nitrogen Mustard Compounds; Recurrence; Treatment Outcome | 2013 |
[Preliminary results of cyclically alternating chemotherapy (CVPP/DBVCy) in advanced Hodgkin's disease].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bleomycin; Clinical Trials as Topic; Daunorubicin; Drug Administration Schedule; Female; Hodgkin Disease; Humans; Lomustine; Male; Middle Aged; Nitrogen Mustard Compounds; Prednisone; Procarbazine; Random Allocation; Vinblastine; Vincristine | 1987 |
42 other study(ies) available for bendamustine hydrochloride and Granuloma, Hodgkin
| Article | Year |
|---|---|
Brentuximab vedotin and bendamustine: an effective salvage therapy for relapsed or refractory Hodgkin lymphoma patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Brentuximab Vedotin; Hodgkin Disease; Humans; Immunoconjugates; Neoplasm Recurrence, Local; Retrospective Studies; Salvage Therapy; Treatment Outcome | 2022 |
Combination brentuximab vedotin and bendamustine for pediatric patients with relapsed/refractory Hodgkin lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Brentuximab Vedotin; Child; Hodgkin Disease; Humans; Retrospective Studies; Treatment Outcome; Young Adult | 2021 |
Brentuximab Vedotin and Bendamustine Produce Long-Term Clinical Benefit in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter Real-Life Experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Brentuximab Vedotin; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunoconjugates; Neoplasm Recurrence, Local; Transplantation, Autologous; Treatment Outcome | 2022 |
Brentuximab vedotin in combination with bendamustine in pediatric patients or young adults with relapsed or refractory Hodgkin lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Brentuximab Vedotin; Child; Hodgkin Disease; Humans; Immunoconjugates; Neoplasm Recurrence, Local; Retrospective Studies; Treatment Outcome; Young Adult | 2022 |
Favorable outcomes of allogeneic hematopoietic stem cell transplantation with fludarabine-bendamustine conditioning and posttransplantation cyclophosphamide in classical Hodgkin lymphoma.
Topics: Adult; Bendamustine Hydrochloride; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Neoplasm Recurrence, Local; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2022 |
Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Brentuximab Vedotin; Chronic Disease; Hodgkin Disease; Humans; Lymphoma, T-Cell, Peripheral; Neoplasm Recurrence, Local; Retrospective Studies; Salvage Therapy; Treatment Outcome | 2023 |
Brentuximab vedotin plus bendamustine versus platinum-based regimens as 1st salvage therapy and 'bridge' to autologous hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma.
Topics: Bendamustine Hydrochloride; Brentuximab Vedotin; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunoconjugates; Neoplasm Recurrence, Local; Salvage Therapy; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome | 2023 |
Queen's gambit: response-adapted win in CAYA with cHL.
Topics: Adolescent; Bendamustine Hydrochloride; Brentuximab Vedotin; Child; Hodgkin Disease; Humans; Nivolumab; Young Adult | 2023 |
Determination of Bendamustine, Gemcitabine and Vinorelbine (BEGEV) regimen in spiked human plasma using multivariate model update chemometric methods.
Topics: Bendamustine Hydrochloride; Chemometrics; Chromatography, Liquid; Gemcitabine; Hodgkin Disease; Humans; Tandem Mass Spectrometry; Vinorelbine | 2023 |
Pharmacokinetics and safety of bendamustine in the BEABOVP regimen for the treatment of pediatric patients with Hodgkin lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Child; Doxorubicin; Hodgkin Disease; Humans; Mechlorethamine; Neoplasm Recurrence, Local | 2023 |
R-bendamustine in the treatment of nodular lymphocyte predominant Hodgkin lymphoma-An extended follow-up.
Topics: Bendamustine Hydrochloride; Follow-Up Studies; Hodgkin Disease; Humans; Lymph Nodes; Lymphocytes | 2023 |
Nivolumab plus Brentuximab vedotin +/- bendamustine combination therapy: a safe and effective treatment in pediatric recurrent and refractory classical Hodgkin lymphoma.
Topics: Bendamustine Hydrochloride; Brentuximab Vedotin; Child; Hodgkin Disease; Humans; Nivolumab; Treatment Outcome | 2023 |
Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30-positive aggressive lymphomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Brentuximab Vedotin; Child; Combined Modality Therapy; Female; Hodgkin Disease; Humans; Induction Chemotherapy; Ki-1 Antigen; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Prognosis; Treatment Outcome; Young Adult | 2020 |
Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma.
Topics: Antineoplastic Agents, Immunological; Bendamustine Hydrochloride; Brentuximab Vedotin; Female; Hodgkin Disease; Humans; Male; Salvage Therapy; Survival Analysis; Time Factors; Treatment Outcome | 2020 |
Brentuximab vedotin in association with bendamustine in refractory or multiple relapsed Hodgkin lymphoma. A retrospective real-world study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Brentuximab Vedotin; Combined Modality Therapy; Drug Resistance, Neoplasm; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Recurrence; Treatment Outcome; Young Adult | 2020 |
Real-world efficacy of brentuximab vedotin plus bendamustine as a bridge to autologous hematopoietic stem cell transplantation in primary refractory or relapsed classical Hodgkin lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Brentuximab Vedotin; Combined Modality Therapy; Drug Evaluation; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multicenter Studies as Topic; Neutropenia; Peripheral Nervous System Diseases; Positron-Emission Tomography; Progression-Free Survival; Retrospective Studies; Salvage Therapy; Transplantation, Autologous; Treatment Outcome; Young Adult | 2020 |
The addition of bendamustine to brentuximab vedotin leads to improved rates of complete metabolic remission in children, adolescents and young adults with relapsed and refractory classical Hodgkin lymphoma: a retrospective single-centre series.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Brentuximab Vedotin; Child; Female; Hodgkin Disease; Humans; Male; Neoplasm Recurrence, Local; Treatment Outcome; Young Adult | 2021 |
Bendamustine as a bridge to allogeneic transplant in relapsed/refractory Hodgkin lymphoma patients who failed salvage brentuximab vedotin postautologous peripheral blood stem cell transplantation.
Topics: Adolescent; Adult; Bendamustine Hydrochloride; Brentuximab Vedotin; Combined Modality Therapy; Hodgkin Disease; Humans; Immunoconjugates; Middle Aged; Neoplasm Staging; Peripheral Blood Stem Cell Transplantation; Positron Emission Tomography Computed Tomography; Transplantation, Homologous; Treatment Outcome; Young Adult | 2017 |
A retrospective, matched paired analysis comparing bendamustine containing BeEAM versus BEAM conditioning regimen: results from a single center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Carmustine; Case-Control Studies; Cytarabine; Diarrhea; Disease-Free Survival; Drug Resistance, Neoplasm; Etoposide; Female; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous; Young Adult | 2018 |
Salvage regimens for Hodgkin's lymphoma in the brentuximab vedotin era.
Topics: Bendamustine Hydrochloride; Brentuximab Vedotin; Child; Hodgkin Disease; Humans; Immunoconjugates; Salvage Therapy | 2018 |
R-Bendamustine in the treatment of nodular lymphocyte-predominant Hodgkin lymphoma.
Topics: Adult; Bendamustine Hydrochloride; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Hodgkin Disease; Humans; Male; Middle Aged; Neoadjuvant Therapy; Recurrence; Retrospective Studies; Young Adult | 2018 |
Getting to transplant in Hodgkin lymphoma: BVB.
Topics: Bendamustine Hydrochloride; Brentuximab Vedotin; Child; Hodgkin Disease; Humans; Immunoconjugates; Salvage Therapy | 2018 |
Clinical experience of bendamustine in relapsed or refractory Hodgkin lymphoma: a retrospective analysis of the French compassionate use program in 28 patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Compassionate Use Trials; Female; Hodgkin Disease; Humans; Male; Middle Aged; Neoplasm Staging; Nitrogen Mustard Compounds; Recurrence; Retrospective Studies; Treatment Outcome; Young Adult | 2013 |
Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bleomycin; Brentuximab Vedotin; Combined Modality Therapy; Dacarbazine; Doxorubicin; Drug Resistance, Neoplasm; Hodgkin Disease; Humans; Immunoconjugates; Male; Nitrogen Mustard Compounds; Positron-Emission Tomography; Radiotherapy, Adjuvant; Recurrence; Salvage Therapy; Vinblastine; Young Adult | 2013 |
Bendamustine: a bridge to longer term solutions in heavily treated Hodgkin lymphoma.
Topics: Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Female; Hodgkin Disease; Humans; Male; Nitrogen Mustard Compounds | 2013 |
Bendamustine for Hodgkin lymphoma patients failing autologous or autologous and allogeneic stem cell transplantation: a retrospective study of the Fondazione Italiana Linfomi.
Topics: Adult; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Drug Evaluation; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Nitrogen Mustard Compounds; Recurrence; Retrospective Studies; Salvage Therapy; Treatment Failure; Treatment Outcome; Young Adult | 2014 |
Bendamustine treatment in a heavily pretreated Hodgkin lymphoma patient.
Topics: Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Hodgkin Disease; Humans; Male; Middle Aged; Prognosis; Remission Induction | 2014 |
Bendamustine combined with donor lymphocytes infusion in Hodgkin's lymphoma relapsing after allogeneic hematopoietic stem cell transplantation.
Topics: Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphocytes; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Transplantation Conditioning | 2014 |
Impressive response to pegylated liposomal doxorubicin after allogeneic transplantation in a multi-relapsed Hodgkin's lymphoma.
Topics: Allografts; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Brentuximab Vedotin; Carmustine; Combined Modality Therapy; Cytarabine; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunoconjugates; Lenalidomide; Liposomes; Male; Melphalan; Polyethylene Glycols; Recurrence; Remission Induction; Salvage Therapy; Thalidomide; Transplantation, Autologous; Young Adult | 2016 |
Safety and efficacy of single-agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory hodgkin's lymphoma: experience with 27 patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Brentuximab Vedotin; Drug Resistance, Neoplasm; Female; Hodgkin Disease; Humans; Immunoconjugates; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Treatment Failure; Young Adult | 2015 |
[Novel treatment options in relapsed and refracter Hodgkin lymphomas].
Topics: Adult; Antineoplastic Agents; B7-H1 Antigen; Bendamustine Hydrochloride; Brentuximab Vedotin; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Hungary; Immunoconjugates; Male; Middle Aged; Neoplasm Recurrence, Local; Recurrence; Retrospective Studies; Rituximab; Salvage Therapy; Sclerosis; Survival Analysis; Survival Rate; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome | 2015 |
Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bendamustine Hydrochloride; Brentuximab Vedotin; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Hodgkin Disease; Humans; Immunoconjugates; Male; Middle Aged; Treatment Outcome | 2016 |
Treating the Hodgkin's Lymphoma Variant of Richter's Transformation.
Topics: Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell | 2016 |
Bendamustine combined regimen for Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Clinical Trials, Phase II as Topic; Disease Progression; Disease-Free Survival; Hodgkin Disease; Humans; Remission Induction; Treatment Outcome | 2016 |
Bendamustine can be a bridge to allogeneic transplantation in relapsed Hodgkin lymphoma refractory to brentuximab vedotin.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Brentuximab Vedotin; Drug Resistance, Neoplasm; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunoconjugates; Recurrence; Retreatment; Transplantation, Homologous; Treatment Outcome | 2017 |
Brentuximab vedotin and bendamustine produce high complete response rates in patients with chemotherapy refractory Hodgkin lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Brentuximab Vedotin; Female; Hodgkin Disease; Humans; Immunoconjugates; Male; Middle Aged; Treatment Outcome; Young Adult | 2018 |
Eleventh biannual report of the Cochrane Haematological Malignancies Group: Focus on Hodgkin lymphoma.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bendamustine Hydrochloride; Bleomycin; Chlorambucil; Controlled Clinical Trials as Topic; Cyclophosphamide; Dacarbazine; Doxorubicin; Etoposide; Exercise; Hematinics; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Multicenter Studies as Topic; Myelodysplastic Syndromes; Nitrogen Mustard Compounds; Prednisone; Procarbazine; Quality of Life; Randomized Controlled Trials as Topic; Vinblastine; Vincristine | 2010 |
Efficacy of bendamustine as salvage treatment in an heavily pre-treated Hodgkin lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Hodgkin Disease; Humans; Male; Nitrogen Mustard Compounds; Treatment Outcome | 2010 |
Successful administration of rituximab-bendamustine regimen in the relapse of Hodgkin lymphoma after autologous hemopoietic stem cell transplantation.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Nitrogen Mustard Compounds; Recurrence; Rituximab; Salvage Therapy; Transplantation, Autologous | 2012 |
Bendamustine salvage for the treatment of relapsed Hodgkin's lymphoma after allogeneic bone marrow transplantation.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bleomycin; Bone Marrow Transplantation; Chemical and Drug Induced Liver Injury; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Deoxycytidine; Doxorubicin; Etoposide; Fatal Outcome; Female; Gemcitabine; Graft vs Host Disease; Hodgkin Disease; Humans; Ifosfamide; Male; Nitrogen Mustard Compounds; Prednisolone; Prednisone; Procarbazine; Recurrence; Reoperation; Rituximab; Salvage Therapy; Transplantation, Autologous; Transplantation, Homologous; Vinblastine; Vincristine; Vinorelbine; Young Adult | 2013 |
Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cell Cycle Checkpoints; Combined Modality Therapy; Disease-Free Survival; DNA Repair; Drug Evaluation; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Middle Aged; Nitrogen Mustard Compounds; Off-Label Use; Recurrence; Retrospective Studies; Salvage Therapy; Transplantation, Homologous; Treatment Outcome; Young Adult | 2013 |
Bendamustine in the treatment of hematologic malignancies. Introduction.
Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Hematologic Neoplasms; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Multiple Myeloma; Nitrogen Mustard Compounds | 2002 |